Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2014 5
2015 4
2016 5
2017 11
2018 5
2019 2
2020 8
2021 9
2022 20
2023 20
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Results by year

Filters applied: . Clear all
Page 1
First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial.
Liu SM, Tu HY, Wei XW, Yan HH, Dong XR, Cui JW, Zhou Z, Xu CR, Zheng MY, Li YS, Wang Z, Bai XY, Li AN, Sun YL, Huang J, Lin JX, Ke EE, Xu BF, Lu C, Du Y, Chen Y, Ma R, Wang BH, Cang SD, Wang BC, Chen HJ, Yang JJ, Li Y, Zhou Q, Wu YL. Liu SM, et al. Nat Med. 2023 Aug;29(8):2079-2086. doi: 10.1038/s41591-023-02461-x. Epub 2023 Jul 24. Nat Med. 2023. PMID: 37488286 Clinical Trial.
2D quasi-layered material with domino structure.
Lan H, Wang L, He R, Huang S, Yu J, Guo J, Luo J, Li Y, Zhang J, Lin J, Zhang S, Zeng M, Fu L. Lan H, et al. Among authors: lin j. Nat Commun. 2023 Nov 9;14(1):7225. doi: 10.1038/s41467-023-42818-x. Nat Commun. 2023. PMID: 37940641 Free PMC article.
Genomic and immune characteristics of HER2-mutated non-small-cell lung cancer and response to immune checkpoint inhibitor-based therapy.
Tu HY, Yin K, Zhao X, Ke EE, Wu SP, Li YS, Zheng MM, Liu SM, Xu CR, Sun YL, Lin JX, Bai XY, Zhang YC, Zhou Q, Yang JJ, Zhong WZ, Wang BC, Zhang XC, Zhu D, Yang L, Ou Q, Wu YL. Tu HY, et al. Mol Oncol. 2023 Aug;17(8):1581-1594. doi: 10.1002/1878-0261.13439. Epub 2023 Apr 29. Mol Oncol. 2023. PMID: 37078460 Free PMC article.
PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial.
Maggie Liu SY, Huang J, Deng JY, Xu CR, Yan HH, Yang MY, Li YS, Ke EE, Zheng MY, Wang Z, Lin JX, Gan B, Zhang XC, Chen HJ, Wang BC, Tu HY, Yang JJ, Zhong WZ, Li Y, Zhou Q, Wu YL. Maggie Liu SY, et al. Sci Bull (Beijing). 2024 Feb 26;69(4):535-543. doi: 10.1016/j.scib.2023.12.046. Epub 2023 Dec 26. Sci Bull (Beijing). 2024. PMID: 38185589 Free article. Clinical Trial.
87 results